Di C, Syafrizayanti C, Zhang Q, Chen Y, Wang Y, Zhang X, et al. Function, clinical application, and strategies of Pre-mRNA splicing in cancer. Cell Death Differ. 2019;26:1181–94.
Gimeno-Valiente F, Lopez-Rodas G, Castillo J, Franco L. Alternative Splicing, Epigenetic Modifications and Cancer: A Dangerous Triangle, or a Hopeful One? Cancers (Basel). 2022;14:560
Rahhal R, Seto E. Emerging roles of histone modifications and HDACs in RNA splicing. Nucleic Acids Res. 2019;47:4911–26.
Bozic T, Frobel J, Raic A, Ticconi F, Kuo CC, Heilmann-Heimbach S, et al. Variants of DNMT3A cause transcript-specific DNA methylation patterns and affect hematopoiesis. Life Sci Alliance. 2018;1:e201800153.
Zhang J, Gao X, Yu L. Roles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins. Front Oncol. 2021;11:741746.
Khan DH, Gonzalez C, Cooper C, Sun JM, Chen HY, Healy S, et al. RNA-dependent dynamic histone acetylation regulates MCL1 alternative splicing. Nucleic Acids Res. 2014;42:1656–70.
Lowe M, Lage J, Paatela E, Munson D, Hostager R, Yuan C, et al. Cry2 Is Critical for Circadian Regulation of Myogenic Differentiation by Bclaf1-Mediated mRNA Stabilization of Cyclin D1 and Tmem176b. Cell Rep. 2018;22:2118–32.
Jiang T, Liu B, Wu D, Zhang F. BCLAF1 induces cisplatin resistance in lung cancer cells. Oncol Lett. 2020;20:227.
Shen B, Tan M, Mu X, Qin Y, Zhang F, Liu Y, et al. Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy. Tumour Biol. 2016;37:7371–81.
Liu H, Lu ZG, Miki Y, Yoshida K. Protein kinase C delta induces transcription of the TP53 tumor suppressor gene by controlling death-promoting factor Btf in the apoptotic response to DNA damage. Mol Cell Biol. 2007;27:8480–91.
Savage KI, Gorski JJ, Barros EM, Irwin GW, Manti L, Powell AJ, et al. Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability. Mol Cell. 2014;54:445–59.
Jiang K, Ding Y, Dong C, Shan F, Guo K, Zhang J, et al. BCLAF1, a functional partner of BACH1, participates in DNA damage response. DNA Repair (Amst). 2022;118:103371.
Zhao S, Pan T, Deng J, Cao L, Vicencio JM, Liu J, et al. Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer. Br J Cancer. 2023;128:665–77.
Renert AF, Leprince P, Dieu M, Renaut J, Raes M, Bours V, et al. The proapoptotic C16-ceramide-dependent pathway requires the death-promoting factor Btf in colon adenocarcinoma cells. J Proteome Res. 2009;8:4810–22.
Yu Z, Zhu J, Wang H, Li H, Jin X. Function of BCLAF1 in human disease. Oncol Lett. 2022;23:58.
Dell’Aversana C, Giorgio C, D’Amato L, Lania G, Matarese F, Saeed S, et al. miR-194-5p/BCLAF1 deregulation in AML tumorigenesis. Leukemia. 2017;31:2315–25.
Zhou X, Li X, Cheng Y, Wu W, Xie Z, Xi Q, et al. BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells. Nat Commun. 2014;5:4581.
Gatto S, Gagliardi M, Franzese M, Leppert S, Papa M, Cammisa M, et al. ICF-specific DNMT3B dysfunction interferes with intragenic regulation of mRNA transcription and alternative splicing. Nucleic Acids Res. 2017;45:5739–56.
Liu Z, Spiegelman VS, Wang HG. Distinct noncoding RNAs and RNA binding proteins associated with high-risk pediatric and adult acute myeloid leukemias detected by regulatory network analysis. Cancer Rep (Hoboken). 2022;5:e1592.
[cited]Available from: www.cbs.dtu.dk/services/NetNES/
Cheung PWLRVCMLW. Abstract 2563: Identifying BCLAF1 as a downstream effector of p85β in ovarian cancer. Cancer Res (2023) 83 (7_Supplement): 2563 2023, Volume 83, Issue 7_Supplement.
Ramabadran R, Wang JH, Reyes JM, Guzman AG, Gupta S, Rosas C, et al. DNMT3A-coordinated splicing governs the stem state switch towards differentiation in embryonic and haematopoietic stem cells. Nat Cell Biol. 2023;25:528–39.
